337 related articles for article (PubMed ID: 26954606)
1. Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.
Aboalhaija NH; Zihlif MA; Taha MO
Chem Biol Interact; 2016 Apr; 250():12-26. PubMed ID: 26954606
[TBL] [Abstract][Full Text] [Related]
2. Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors.
AlQudah DA; Zihlif MA; Taha MO
Eur J Med Chem; 2016 Mar; 110():204-23. PubMed ID: 26840362
[TBL] [Abstract][Full Text] [Related]
3. Elaborate ligand-based modeling coupled with multiple linear regression and k nearest neighbor QSAR analyses unveiled new nanomolar mTOR inhibitors.
Khanfar MA; Taha MO
J Chem Inf Model; 2013 Oct; 53(10):2587-612. PubMed ID: 24050502
[TBL] [Abstract][Full Text] [Related]
4. Unsupervised pharmacophore modeling combined with QSAR analyses revealed novel low micromolar SIRT2 inhibitors.
Khanfar MA; Taha MO
J Mol Recognit; 2017 Sep; 30(9):. PubMed ID: 28299833
[TBL] [Abstract][Full Text] [Related]
5. Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.
Al-Nadaf AH; Taha MO
J Mol Graph Model; 2011 Apr; 29(6):843-64. PubMed ID: 21376648
[TBL] [Abstract][Full Text] [Related]
6. Ligand-based computational modelling of platelet-derived growth factor beta receptor leading to new angiogenesis inhibitory leads.
Al-Aqtash RA; Zihlif MA; Hammad H; Nassar ZD; Meliti JA; Taha MO
Comput Biol Chem; 2017 Dec; 71():170-179. PubMed ID: 29101826
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling.
Mera WA; Alzihlif M; Taha MO; Khanfar MA
Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling.
Khanfar MA; Al-Qtaishat S; Habash M; Taha MO
Chem Biol Interact; 2016 Jul; 254():93-101. PubMed ID: 27216633
[TBL] [Abstract][Full Text] [Related]
9. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent NEK2 inhibitors as potential anticancer agents using structure-based exploration of NEK2 pharmacophoric space coupled with QSAR analyses.
Khanfar MA; Banat F; Alabed S; Alqtaishat S
Mol Divers; 2017 Feb; 21(1):187-200. PubMed ID: 27599492
[TBL] [Abstract][Full Text] [Related]
11. Importance of functional groups in predicting the activity of small molecule inhibitors for Bcl-2 and Bcl-xL.
Kanakaveti V; Sakthivel R; Rayala SK; Gromiha MM
Chem Biol Drug Des; 2017 Aug; 90(2):308-316. PubMed ID: 28112863
[TBL] [Abstract][Full Text] [Related]
12. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new heat shock protein 90 inhibitors using virtual co-crystallized pharmacophore generation.
Al-Sha'er MA; Mansi I; Khanfar M; Abudayyh A
J Enzyme Inhib Med Chem; 2016; 31(sup4):64-77. PubMed ID: 27569779
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling.
Zalloum H; Tayyem R; Irmaileh BA; Bustanji Y; Zihlif M; Mohammad M; Rjai TA; Mubarak MS
J Mol Graph Model; 2015 Sep; 61():61-84. PubMed ID: 26188796
[TBL] [Abstract][Full Text] [Related]
15. Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Taha MO; Al-Sha'er MA; Khanfar MA; Al-Nadaf AH
Eur J Med Chem; 2014 Sep; 84():454-65. PubMed ID: 25050878
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent IRAK-4 inhibitors as potential anti-inflammatory and anticancer agents using structure-based exploration of IRAK-4 pharmacophoric space coupled with QSAR analyses.
Khanfar MA; Alqtaishat S
Comput Biol Chem; 2019 Apr; 79():147-154. PubMed ID: 30818109
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
Abu Khalaf R; Abu Sheikha G; Bustanji Y; Taha MO
Eur J Med Chem; 2010 Apr; 45(4):1598-617. PubMed ID: 20116902
[TBL] [Abstract][Full Text] [Related]
18. QSAR-guided pharmacophoric modeling reveals important structural requirements for Polo kinase 1 (Plk1) inhibitors.
Shahin R; Al-Hashimi NN; Daoud NE; Aljamal S; Shaheen O
J Mol Graph Model; 2021 Dec; 109():108022. PubMed ID: 34562852
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Al-Sha'er MA; Khanfar MA; Taha MO
J Mol Model; 2014 Jan; 20(1):2080. PubMed ID: 24469103
[TBL] [Abstract][Full Text] [Related]
20. Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor.
Al-Sha'er MA; Taha MO
J Mol Graph Model; 2018 Aug; 83():153-166. PubMed ID: 29456101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
